[go: up one dir, main page]

EA200800047A1 - Производные пиримидина - Google Patents

Производные пиримидина

Info

Publication number
EA200800047A1
EA200800047A1 EA200800047A EA200800047A EA200800047A1 EA 200800047 A1 EA200800047 A1 EA 200800047A1 EA 200800047 A EA200800047 A EA 200800047A EA 200800047 A EA200800047 A EA 200800047A EA 200800047 A1 EA200800047 A1 EA 200800047A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diseases
pyrimidine
derivatives
formula
compounds
Prior art date
Application number
EA200800047A
Other languages
English (en)
Other versions
EA015890B1 (ru
Inventor
Чи-Фэн Ен
Чэн-Кун Ху
Мин-Чэнь Чоу
Чэнь-Тсо Тсэн
Чиэнь-Хуан У
Ин-Хуэй Хуан
Шу-Цзэн Чэнь
Чи-Син Ричард Кинг
Original Assignee
Тайджен Байотекнолоджи Ко. Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тайджен Байотекнолоджи Ко. Лтд. filed Critical Тайджен Байотекнолоджи Ко. Лтд.
Publication of EA200800047A1 publication Critical patent/EA200800047A1/ru
Publication of EA015890B1 publication Critical patent/EA015890B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)

Abstract

Настоящее изобретение относится к способу лечения воспалительных или иммунопатологических заболеваний, болезней роста или дегенеративных заболеваний или повреждений тканей. Способ включает введение субъекту, который нуждается в лечении, эффективного количества одного или нескольких соединений формулы (I). Каждая изменяемая группа в представленной формуле определена в описании.
EA200800047A 2005-06-14 2006-06-13 Производные пиримидина EA015890B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69026705P 2005-06-14 2005-06-14
US79859606P 2006-05-08 2006-05-08
PCT/US2006/022975 WO2006138304A2 (en) 2005-06-14 2006-06-13 Pyrimidine compounds

Publications (2)

Publication Number Publication Date
EA200800047A1 true EA200800047A1 (ru) 2008-08-29
EA015890B1 EA015890B1 (ru) 2011-12-30

Family

ID=37571066

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800047A EA015890B1 (ru) 2005-06-14 2006-06-13 Производные пиримидина

Country Status (10)

Country Link
US (2) US20060281712A1 (ru)
EP (1) EP1890703B1 (ru)
JP (1) JP5118029B2 (ru)
KR (1) KR101354114B1 (ru)
AU (1) AU2006259525B2 (ru)
CA (1) CA2612227C (ru)
EA (1) EA015890B1 (ru)
NZ (1) NZ564222A (ru)
TW (1) TWI376376B (ru)
WO (1) WO2006138304A2 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2608315C2 (ru) * 2012-01-16 2017-01-17 Инститьют Оф Фармаколоджи Энд Токсиколоджи Академи Оф Милитари Медикал Сайенсес П.Л.А. Чайна Производные пиперазинил пиримидина, способ их получения и их применение

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193206B2 (en) * 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
CA2612227C (en) * 2005-06-14 2014-04-22 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
EP1942105B8 (en) 2005-10-25 2014-08-13 Shionogi&Co., Ltd. Aminodihydrothiazine derivative
EP2007752B1 (en) * 2006-03-31 2010-08-18 Janssen Pharmaceutica NV Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor
JP5257068B2 (ja) 2006-05-16 2013-08-07 小野薬品工業株式会社 保護されていてもよい酸性基を含有する化合物およびその用途
US20090325992A1 (en) 2006-07-31 2009-12-31 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
NZ579402A (en) * 2007-03-15 2012-03-30 Novartis Ag Organic compounds for diagnosis and treatment of pathologies relating to the Hedgehog pathway
EP2154967B9 (en) 2007-04-16 2014-07-23 Hutchison Medipharma Enterprises Limited Pyrimidine derivatives
RU2476430C2 (ru) 2007-04-24 2013-02-27 Сионоги Энд Ко., Лтд. Производные аминодигидротиазина, замещенные циклической группой
JP5383483B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 アルツハイマー症治療用医薬組成物
FR2915747B1 (fr) * 2007-05-04 2011-02-25 Scras Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatase cdc25
JP2010526048A (ja) * 2007-05-04 2010-07-29 アストラゼネカ アクチボラグ アミノ−チアゾリル−ピリミジン誘導体、および癌の治療のための該誘導体の使用
WO2009026276A1 (en) 2007-08-22 2009-02-26 Irm Llc 5- (4- (haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
US8372849B2 (en) * 2008-04-21 2013-02-12 Taigen Biotechnology Co., Ltd. Heterocyclic compounds
US7829574B2 (en) 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
CA2724737A1 (en) 2008-05-19 2009-11-26 The University Of Tennessee Research Foundation Pyrimidine non-classical cannabinoid compounds and related methods of use
US8389534B2 (en) 2008-05-19 2013-03-05 The University Of Tennessee Research Foundation Pyrimidine non-classical cannabinoid compounds and related methods of use
US8637504B2 (en) 2008-06-13 2014-01-28 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
US8426430B2 (en) 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
TWI481603B (zh) 2008-06-30 2015-04-21 Janssen Pharmaceutica Nv 用於製備經取代之嘧啶衍生物之化合物
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
CN102137857A (zh) 2008-06-30 2011-07-27 詹森药业有限公司 用于制备苯并咪唑-2-基嘧啶衍生物的方法
US20100041663A1 (en) * 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
GB0815369D0 (en) * 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
TW201008933A (en) 2008-08-29 2010-03-01 Hutchison Medipharma Entpr Ltd Pyrimidine compounds
WO2010045377A2 (en) * 2008-10-14 2010-04-22 University Of Tennessee Research Foundation, The Pyrimidine non-classical cannabinoid compounds and related methods of use
CN102186841A (zh) * 2008-10-22 2011-09-14 盐野义制药株式会社 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物
US9023834B2 (en) * 2008-11-13 2015-05-05 Taigen Biotechnology Co., Ltd. Lyophilization formulation
WO2010130900A2 (fr) * 2009-05-15 2010-11-18 Ipsen Pharma S.A.S. Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatases cdc25
FR2945530A1 (fr) * 2009-05-15 2010-11-19 Ipsen Pharma Sas Derives de tri-amino-pyridine comme inhibiteurs de phosphatases cdc25
FR2945532A1 (fr) * 2009-05-15 2010-11-19 Ipsen Pharma Sas Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatases cdc25
CN101716167B (zh) * 2009-12-08 2011-12-28 中国人民解放军军事医学科学院野战输血研究所 一类饱和胺类化合物在制备外周血造血干细胞动员药物中的应用
MX2012006491A (es) 2009-12-11 2012-07-03 Shionogi & Co Derivados de oxazina.
US8431575B2 (en) * 2010-02-18 2013-04-30 Transtech Pharma, Inc. Phenyl-heteroaryl derivatives and methods of use thereof
DK2576541T3 (en) 2010-06-04 2016-05-30 Hoffmann La Roche Aminopyrimidine AS LRRK2 MODULATORS
EP2397482A1 (en) 2010-06-15 2011-12-21 Almirall, S.A. Heteroaryl imidazolone derivatives as jak inhibitors
JP5766198B2 (ja) 2010-10-29 2015-08-19 塩野義製薬株式会社 縮合アミノジヒドロピリミジン誘導体
CN103261199A (zh) 2010-10-29 2013-08-21 盐野义制药株式会社 萘啶衍生物
SI2638031T1 (en) 2010-11-10 2018-02-28 Genentech, Inc. Pyrazole aminopyrimidine derivatives as LRRK2 modulators
TW201247635A (en) 2011-04-26 2012-12-01 Shionogi & Co Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them
EP2912035A4 (en) 2012-10-24 2016-06-15 Shionogi & Co DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY
MX373874B (es) 2013-03-06 2020-03-26 Janssen Pharmaceutica Nv Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina.
RS63190B1 (sr) 2014-08-04 2022-06-30 Nuevolution As Opciono fuzionisani derivati pirimidina zamenjeni heterociklilom korisni za lečenje zapaljenskih, metaboličkih, onkoloških i autoimunskih bolesti
US9708272B2 (en) 2014-08-29 2017-07-18 Tes Pharma S.R.L. Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase
US9375406B2 (en) * 2014-09-30 2016-06-28 Taigen Biotechnology Co., Ltd. Substituted pyrimidines for mobilizing cells expressing a type 4 CXC chemokine receptor
AU2017275657B2 (en) 2016-06-02 2021-08-19 Novartis Ag Potassium channel modulators
AU2018208366B2 (en) 2017-01-10 2020-12-17 National Health Research Institutes Heterocyclic compounds and use thereof
RS62899B1 (sr) 2017-01-23 2022-03-31 Cadent Therapeutics Inc Modulatori kalijumovih kanala
MX2021004647A (es) 2018-10-22 2021-08-16 Novartis Ag Formas cristalinas de moduladores de los canales de potasio.
CN113412258A (zh) 2019-01-18 2021-09-17 阿斯利康(瑞典)有限公司 Pcsk9抑制剂及其使用方法
US11685727B2 (en) 2019-12-20 2023-06-27 Nuevolution A/S Compounds active towards nuclear receptors
AU2020405446A1 (en) 2019-12-20 2022-05-26 Nuevolution A/S Compounds active towards nuclear receptors
EP4126875A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
MX2022012260A (es) 2020-03-31 2022-11-30 Nuevolution As Compuestos activos frente a receptores nucleares.
WO2022216097A1 (ko) * 2021-04-08 2022-10-13 주식회사 스탠다임 신규한 lrrk2 억제제
CN118076601A (zh) * 2021-08-02 2024-05-24 台湾卫生研究院 嘧啶化合物及其用途
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3759921A (en) * 1969-10-16 1973-09-18 Lilly Co Eli Method of suppressing immuneresponse with 1 substituted-3-(2 pyrimidyl)ureas
DE2853220A1 (de) * 1978-12-09 1980-07-03 Hoechst Ag Neue amino-pyrimidin-carbanilide, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
LU86960A1 (fr) * 1987-07-31 1989-03-08 Oreal Procede de preparation de piperidino-6 diamino-2,4 pyrimidine oxyde-3 et composes nouveaux
JPH04211040A (ja) * 1990-02-22 1992-08-03 Sumitomo Pharmaceut Co Ltd トリアミン誘導体及びその酸付加塩
US5034560A (en) * 1990-10-19 1991-07-23 The Standard Oil Company Synthesis of ethylamines
AU667051B2 (en) 1991-07-04 1996-03-07 Dako Denmark A/S Water-soluble, polymer-based reagents and conjugates comprising moieties derived from divinyl sulfone
IT1250749B (it) * 1991-08-02 1995-04-21 Luso Farmaco Inst Composti eterociclici ad attivita' a ii antagonista
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
IL112795A (en) 1994-03-04 2001-01-28 Astrazeneca Ab Peptide derivatives as antithrombic agents their preparation and pharmaceutical compositions containing them
AU7692996A (en) 1995-12-01 1997-06-27 Ciba-Geigy Ag Receptor antagonists
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
WO1997046250A1 (en) 1996-06-04 1997-12-11 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and dna encoding a hypothalamic atypical neuropeptide y/peptide yy receptor (y5)
NO311614B1 (no) 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
WO1998024782A2 (en) 1996-12-05 1998-06-11 Amgen Inc. Substituted pyrimidine compounds and their use
EP0973767A1 (en) * 1997-03-31 2000-01-26 Dupont Pharmaceuticals Company Indazoles of cyclic ureas useful as hiv protease inhibitors
CA2333927A1 (en) 1998-04-01 1999-10-07 Dupont Pharmaceuticals Company Pyrimidines and triazines as integrin antagonists
US6420354B1 (en) * 1998-06-08 2002-07-16 Advanced Medicine, Inc. Sodium channel drugs and uses
ATE274510T1 (de) * 1998-06-19 2004-09-15 Chiron Corp Glycogen synthase kinase 3 inhibitoren
SI20746A (sl) 1998-08-20 2002-06-30 Agouron Pharmaceuticals, Inc. Nepeptidni GnRH agensi ter metode in vmesne spojine za njihovo pripravo
DE19851421A1 (de) * 1998-11-07 2000-05-11 Boehringer Ingelheim Pharma Neue Pyrimidine, deren Herstellung und Verwendung
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
US6274588B1 (en) 1999-05-31 2001-08-14 Hoffmann-La Roche Inc. 4-phenyl-pyrimidine derivatives
DE60043397D1 (de) 1999-12-28 2010-01-07 Pharmacopeia Inc Cytokine, insbesondere tnf-alpha, hemmer
WO2002059111A2 (en) 2000-12-21 2002-08-01 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
CN101851173A (zh) 2001-09-14 2010-10-06 梅特希尔基因公司 组蛋白脱乙酰化酶抑制剂
WO2003026664A1 (en) * 2001-09-26 2003-04-03 Bayer Corporation 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
AU2002334733B2 (en) 2001-10-01 2006-11-23 Arena Pharmaceuticals, Inc. MCH receptors antagonists
WO2003082855A1 (en) * 2002-03-28 2003-10-09 Kyowa Hakko Kogyo Co., Ltd. Anti-inflammatory agent
CN1665789A (zh) * 2002-06-28 2005-09-07 山之内制药株式会社 二氨基嘧啶酰胺衍生物
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
JP2006514989A (ja) * 2002-07-29 2006-05-18 ライジェル ファーマシューティカルズ ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療および予防方法
AU2003284632A1 (en) * 2002-11-22 2004-06-18 Mitsubishi Pharma Corporation Isoquinoline compounds and medicinal use thereof
PL377795A1 (pl) * 2002-11-28 2006-02-20 Schering Aktiengesellschaft Pirymidyny będące inhibitorami Chk, Pdk i Akt, sposób ich wytwarzania oraz ich zastosowanie jako środków farmaceutycznych
US7759336B2 (en) * 2002-12-10 2010-07-20 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compounds and medicinal use thereof
CA2514612A1 (en) * 2003-01-30 2004-08-12 Boehringer Ingelheim Pharmaceuticals, Inc. 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta
US20060194811A1 (en) * 2003-02-21 2006-08-31 Kyowa Hakko Kogyo Co., Ltd. Pyrimidine derivatives
EP1464335A3 (en) * 2003-03-31 2007-05-09 Taisho Pharmaceutical Co. Ltd. Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist
AU2004274155A1 (en) * 2003-09-22 2005-03-31 F. Hoffmann-La Roche Ag Aminoalkylamide substituted cyclohexyl derivatives
JP2007217282A (ja) * 2004-03-04 2007-08-30 Astellas Pharma Inc 置換ピリミジン誘導体
US8367038B2 (en) * 2004-05-23 2013-02-05 HMI Medical Innovations, LLC Therameutin modulators
WO2006025567A1 (ja) * 2004-08-31 2006-03-09 Banyu Pharmaceutical Co., Ltd. 新規置換イミダゾール誘導体
RU2007120685A (ru) * 2004-11-03 2008-12-10 Ф.Хоффманн-Ля Рош Аг (Ch) ДИКАРБОКСАМИДНЫЕ ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Ха
JP2006188445A (ja) * 2005-01-05 2006-07-20 Ono Pharmaceut Co Ltd 含窒素複素環化合物およびその医薬用途
EP1852432A4 (en) * 2005-02-25 2010-04-14 Ono Pharmaceutical Co NITROGENIC HETEROCYCLIC COMPOUND AND THEIR MEDICAL USE
WO2007037898A2 (en) * 2005-08-29 2007-04-05 Housey Pharmaceuticals Inc Theramutein modulators
CA2612227C (en) 2005-06-14 2014-04-22 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
JP5335426B2 (ja) * 2005-09-27 2013-11-06 アイアールエム・リミテッド・ライアビリティ・カンパニー ジアリールアミン含有化合物および組成物、ならびにｃ−ｋｉｔ受容体のモジュレーターとしてのそれらの使用
AU2006318383A1 (en) * 2005-11-23 2007-05-31 Gerard M. Housey Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators
UY30117A1 (es) * 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
KR20090052301A (ko) * 2006-03-16 2009-05-25 노파르티스 아게 특히 흑색종의 치료를 위한 헤테로고리형 유기 화합물
WO2007129195A2 (en) * 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2608315C2 (ru) * 2012-01-16 2017-01-17 Инститьют Оф Фармаколоджи Энд Токсиколоджи Академи Оф Милитари Медикал Сайенсес П.Л.А. Чайна Производные пиперазинил пиримидина, способ их получения и их применение

Also Published As

Publication number Publication date
AU2006259525A1 (en) 2006-12-28
US7589197B2 (en) 2009-09-15
TWI376376B (en) 2012-11-11
JP2008546698A (ja) 2008-12-25
KR101354114B1 (ko) 2014-01-24
EP1890703A2 (en) 2008-02-27
JP5118029B2 (ja) 2013-01-16
CA2612227A1 (en) 2006-12-28
AU2006259525B2 (en) 2012-05-24
NZ564222A (en) 2011-10-28
CA2612227C (en) 2014-04-22
KR20080036038A (ko) 2008-04-24
EP1890703B1 (en) 2016-05-11
US20060293324A1 (en) 2006-12-28
US20060281712A1 (en) 2006-12-14
HK1121062A1 (en) 2009-04-17
WO2006138304A3 (en) 2007-05-24
EA015890B1 (ru) 2011-12-30
WO2006138304A2 (en) 2006-12-28
EP1890703A4 (en) 2010-11-03
TW200716612A (en) 2007-05-01

Similar Documents

Publication Publication Date Title
EA200800047A1 (ru) Производные пиримидина
EA200802213A1 (ru) Способы лечения заболеваний крови
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
EA200970575A1 (ru) Соединения на основе 4-фенил-6-(2,2,2-трифтор-1-фенилэтокси)пиримидина и способы их применения
EA201200669A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EA201000098A1 (ru) Производные хиназолинамида
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
EA200800760A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EA200971104A1 (ru) Производные бензимидазола
EA201071264A1 (ru) Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера
EA201001455A1 (ru) Пиридины и пиразины в качестве ингибиторов pi3k (фосфатидилинозиткиназы-3)
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
EA201000552A1 (ru) Производные пирроло[2,3-d]пиримидина в качестве ингибиторов протеинкиназы в
EA201100794A1 (ru) Замещенные пиримидины, предназначенные для лечения заболеваний, таких как рак
TW200510333A (en) Benzimidazole compounds
EA201000642A1 (ru) 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
EA201170607A1 (ru) Акриламидопроизводные, применимые как ингибиторы перехода митохондриальной проницаемости
EA200702387A1 (ru) Имидазохинолины в качестве ингибиторов липидкиназы
EA200900918A1 (ru) Гетероароилзамещенные серинамиды
EA200701808A1 (ru) Производные тетрагидроиндолона и тетрагидроиндазолона
EA201170521A1 (ru) Новые соединения
ATE530524T1 (de) Substituierte sulfonamid-derivate
EA200701504A1 (ru) Индолы, пригодные для лечения воспалений
EA200801996A1 (ru) 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов
EA201100874A1 (ru) Соединения для лечения рака

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

PC4A Registration of transfer of a eurasian patent by assignment